# NeoVax With Nivolumab in Patients With Ovarian Cancer

> **NCT04024878** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 22 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Nivolumab
- **BIOLOGICAL:** NeoVax
- **PROCEDURE:** Core Needle Biopsy

## Key facts

- **NCT ID:** NCT04024878
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-20
- **Primary completion:** 2025-04-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04024878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04024878, "NeoVax With Nivolumab in Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04024878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*